Low-Dose Naltrexone

“Low Dose Naltrexone (LDN) may well be the most important therapeutic breakthrough in over fifty years. It provides a new method of medical treatment by mobilizing the natural defenses of one’s own immune system.” — David Gluck, MD

FDA-approved Naltrexone, administered in a low dose, can stimulate and improve a person’s overall immune system — in particular, helping those with cancer, HIV/AIDS, autoimmune diseases, and central nervous system disorders.

People who suffer from diseases that are partially or largely generated by a lack of endorphins (such as cancer and autoimmune diseases), or are accelerated by a lack of endorphins (e.g. HIV/AIDS) can benefit from LDN treatment. LDN restores the body’s normal production of endorphins.

How does it work?

LDN causes the body to secrete endorphins (metenkephalin and beta-endorphin), which attach to cancers having opiate receptors, shrinking the tumors and inhibiting their growth. Each individual’s own endorphin secretions (our internal opioids) play a crucial role in assisting the overall optimal functioning of the immune system. It is suggested that the increased endorphin and enkephalin levels, induced by LDN, work directly on the tumors’ opioid receptors — and, perhaps, induce cancer cell death (apoptosis).

Responses to LDN treatment have been seen in patients with a wide variety of cancers, including but not limited to:

  • Colon cancer
  • Pancreatic cancer
  • Brain cancer (including Glioblastoma)
  • Lung cancer
  • Breast cancer
  • Prostate cancer
  • Ovarian cancer
  • Non-Hodgkin’s lymphoma
  • Hodgkin’s Disease
  • Chronic lymphocytic leukemia (CLL)
  • Malignant melanoma
  • Multiple myeloma
  • Neuroblastoma
  • Uterine cancer

 

For More Information Please Visit: http://lowdosenaltrexone.org/